Skip to main content
Midas Edge

Citius Pharmaceuticals, Inc.

For the period ended Dec 31, 2025. Filed Feb 13, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2025 · Filed Feb 13, 2026

CTXR$0.53-3.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 6. Exhibits

4.1Form of Warrant issued on October 21, 2025 (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on October 21, 2025).
4.2Form of Pre-Funded Warrant issued on October 21, 2025 (incorporated by reference to Exhibit 4.2 to the Form 8-K filed on October 21, 2025).
4.3Form of Placement Agent Warrant issued on October 21, 2025 (incorporated by reference to Exhibit 4.3 to the Form 8-K filed on October 21, 2025).
4.4Form of Warrant issued on December 2, 2025 (incorporated by reference to Exhibit 4.31 to the Form 10-K filed on December 23, 2025).
10.1Form of Securities Purchase Agreement, dated as of October 20, 2025, by and among Citius Pharmaceuticals, Inc. and the investor signatory thereto (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on October 21, 2025).
10.2Second Amendment to Promissory Note, dated December 10, 2025, by and between Citius Oncology, Inc. and Citius Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.38 to the Form 10-K filed on December 23, 2025).
10.3Amendment No. 1 to Unsecured Promissory Note issued to Pagoda Resources, Inc., dated December 2, 2025 (incorporated by reference to Exhibit 10.45 to the Form 10-K filed on December 23, 2025).
10.4Second Amendment to Amended and Restated Employment Agreement by and between Myron Holubiak and Citius Pharmaceuticals, Inc., executed December 23, 2025, effective October 31, 2025 (incorporated by reference to Exhibit 10.49 to the Form 10-K filed on December 23, 2025).
31.1Certification of the Principal Executive Officer pursuant to Exchange Act Rule 13a-14(a).*
31.2Certification of the Principal Financial Officer pursuant to Exchange Act Rule 13a-14(a).*
32.1Certification of the Principal Executive and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.*
EX-101.INSInline XBRL Instance Document*
EX-101.SCHInline XBRL Taxonomy Extension Schema Document*
EX-101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document*
EX-101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document*
EX-101.LABInline XBRL Taxonomy Extension Label Linkbase Document*
EX-101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document*
EX-104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*
*Filed herewith.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.